Amphivena Therapeutics is a San Francisco-based preclinical stage firm that develops a revolutionary immunotherapy for treating hematologic malignancies. During its Series A funding of July 2013, the company raised a record $14 million. MPM Capital oversaw the fundraising campaign. Amphivena Therapeutics’ goal is to eliminate blood cancer with an advanced therapy that couples with the immune system of the patient to destroy the cancerous cells and their precursors. Dr. JeanMarie Guenot, the CEO of Amphivena, is recognized for creating and operating SKS Ocular, a leading ophthalmic company incubator that specializes in dry AMD, continuous release ocular medication delivery techniques, and innovative therapies for macular degeneration, glaucoma, and ocular inflammation.
Who is CEO JeanMarie Guenot?
Guenot’s biography page describes her as a shrewd investor, scientist, and an active philanthropist. She began her professional business career as a senior employee of Atlas Venture. She oversaw venture capital investments and created life science firms from scratch. In the science world, Guenot started as a principle scientist in Hoffmann-La Roche’s Preclinical R&D. She focused on discovering and creating medications for autoimmune diseases, inflammation, oncology, and metabolic diseases.
On her Facebook page Dr. Guenot lists that she majored in physical and medical chemistry with a special focus on semi-empirical and quantum mechanical techniques for protein structure prediction, molecular dynamics, drug design, and X-ray and NMR refinement. She received her Ph.D. from the San Francisco-based University of California and her MBA from the University of Pennsylvania. Dr. Guenot fulfills her continuous education requirement by participating actively in research and attending educational workshops.
Dr. Guenot’s unmatched experience in the pharmaceutical and biotechnological sector extends for more than 20 years. She has a professional expertise of working with both private and public companies. Her portfolio consists of venture capitalism, commercial & corporate development, pharmaceutical R&D, project & alliance management, and company building or rebuilding.
Early career history
Dr. Guenot served as a business coach for Hoffmann-La Roche. During her tenure as the VP of PDL BioPharma in charge of corporate & business development, she oversaw merger and acquisitions, licensing, and management of alliances. She played an instrumental role in the negotiation of co-commercialization and co-development strategic partnership that comprised of three phase 2 trials for cancer and autoimmune diseases. BusinessWire has more on Jeanmarie’s strategic partnerships, and where she plans to take Amphivena in the future.